TORONTO, Ontario, March 3, 2026
PharmAla Biotech Holdings Inc. has entered a supply and data agreement with Nautilus Sanctuary to provide clinical-grade LaNeo™ MDMA for a Phase 2 clinical trial investigating MDMA-assisted therapy for post-traumatic stress disorder (PTSD) and adjustment disorder in frontline healthcare workers and first responders. The partnership underscores the growing scientific and clinical interest in psychedelic-assisted therapies as potential treatments for trauma-related mental health disorders, while expanding PharmAla’s clinical evidence base supporting the safety and therapeutic potential of MDMA-based medicines.
Phase 2 Study Focuses on Trauma in Frontline Professionals
The collaboration will support an open-label Phase 2 clinical trial in the United States titled “An Open Label Study to Treat Post-Traumatic Stress in Frontline Healthcare Workers and First Responders Using MDMA-Assisted Therapy.” The research aims to evaluate whether MDMA used in combination with structured psychotherapy can help patients process traumatic experiences and reduce symptoms associated with PTSD and adjustment disorder.
Frontline healthcare professionals and emergency responders often face repeated exposure to traumatic events, high-stress working environments, and emotionally demanding situations, placing them at greater risk for long-term mental health conditions. Many individuals in these professions experience persistent trauma-related symptoms such as anxiety, depression, sleep disturbances, and emotional distress, which can significantly affect quality of life and job performance.
Researchers believe MDMA-assisted psychotherapy may enhance emotional processing, reduce fear responses, and strengthen therapeutic engagement, allowing patients to work through traumatic memories more effectively during treatment sessions. Early clinical research in this field has suggested that psychedelic-assisted therapies could represent a promising alternative for patients who do not respond to conventional psychiatric treatments.
Advertisement
Supply-for-Data Model Supports Drug Development
Under the agreement, PharmAla will supply its proprietary LaNeo™ MDMA drug product to Nautilus Sanctuary for use in the clinical trial, ensuring the study uses pharmaceutical-grade material produced under regulated manufacturing standards. PharmAla has developed a cGMP-compliant manufacturing process for MDMA, enabling consistent production of clinical-grade active pharmaceutical ingredients and finished drug products suitable for controlled clinical research.
In exchange for providing the investigational drug, Nautilus Sanctuary will grant PharmAla a perpetual, non-exclusive license to the clinical trial data generated from the study. The agreement allows PharmAla to access pseudonymized and de-identified patient datasets, along with safety and efficacy analyses conducted by the research team.
This arrangement enables PharmAla to use the resulting clinical evidence for regulatory submissions, research development, and commercial purposes in jurisdictions around the world, helping the company strengthen its scientific and regulatory foundation for MDMA-based therapies.
The company describes this arrangement as part of its “supply-for-data” collaboration model, which allows PharmAla to support independent clinical research while expanding its internal knowledge base and regulatory readiness.
Expanding Research in Psychedelic Therapeutics
The partnership reflects broader momentum within the biotechnology industry to explore psychedelic compounds as potential treatments for mental health disorders, particularly conditions associated with trauma and treatment resistance. Scientific research over the past decade has renewed interest in compounds such as MDMA, psilocybin, and related molecules for their ability to facilitate therapeutic breakthroughs when used under controlled clinical conditions.
PharmAla’s research and development efforts focus on the MDXX class of molecules, a group of compounds related to MDMA that may offer therapeutic potential in psychiatric and neurological disorders. In addition to supporting clinical trials using MDMA, the company is conducting preclinical research on novel chemical entities derived from the MDXX molecular family, with early proof-of-concept studies underway.
The company has also recently completed the shipment of LaNeo™ MDMA to University College London for another clinical research program, demonstrating growing international interest in studying psychedelic-assisted therapies in academic and medical research settings.
As research continues to expand, scientists and clinicians hope that carefully controlled psychedelic-assisted treatments could offer new therapeutic options for individuals suffering from severe trauma-related mental health conditions, including those serving on the frontlines of healthcare and emergency response.
If successful, the Phase 2 trial supported by PharmAla and Nautilus Sanctuary could contribute valuable clinical evidence supporting the future regulatory approval and clinical adoption of MDMA-assisted therapy for patients experiencing PTSD and related disorders.
Source: PharmAla Biotech press release
